Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Oncologists (US)

Council Members in this Study Group: 2257

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INCDonald Fleming, MD

Division Head of Hematology and Oncology
DAVIS HEALTH SYSTEM INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...

105 recent news post(s)
Eric Jacobsen, MD

Instructor in Medicine
DANA-FARBER CANCER INSTITUTE, INC.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Eric Jacobsen, MD, is Medical Oncologist and Hematologist in the Hematology/Oncology Department at the Dana-Farber Cancer Institute in Boston, MA. Dr. Jacobsen is a member of the lymphoma and bone marrow transplant divisions at Dana-Farber Cancer Institute and an Instructor in Medicine at HarvardMedical...

Taral Patel, MD, Oncologist, MID-OHIO ONCOLOGY & HEMOTOLOGY INCTaral Patel, MD

Oncologist
MID-OHIO ONCOLOGY & HEMOTOLOGY INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...

8 recent news post(s)
Robert Gilstrap

President
PEACH NET COMMUNICATIONS, INC.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Robert Gilstrap is the President at Peachnet Communications, Inc., a wireless retailer and reseller. Peachnet represents Cingular Wireless, Nextel, T-Mobile, Sprint PCS, DirecTV, Dish Network, Direct-Way, StarBand Sirius Satellite Radio. They also represent smaller companies in the prepaid cellular...

Charles Bennett, M.D., Radiation Oncologist , ROBERT BOISSONEAULT ONCOLOGY INSTITUTECharles Bennett, M.D.

Radiation Oncologist
ROBERT BOISSONEAULT ONCOLOGY INSTITUTE
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Charles Bennett, MD, is a board certified Radiation Oncologist at the Robert Boissoneault Oncology Institute, Florida. He specializes in breast, prostate and metastatic cancer treatment with radiopharmaceauticals. Dr. Bennett has participated in several national forums dealing with radiopharmaceautical...

1 recent news post(s)
Michael Grossbard, MD

Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's...

87 recent news post(s)
Brian Abbott, MD, Medical Director of Hematology, Big Sky OncologyBrian Abbott, MD

Medical Director of Hematology
Big Sky Oncology
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Brian Abbott, MD, is the Medical Director of Hematology at Benefis Health System and Sletten Cancer Institute in Great Falls, Montana. He is also Medical Director of the Palliative Medicine program. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including...

5 recent news post(s)
Sujith Kalmadi

Staff Physician
Ironwood Cancer & Research Center
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Sujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine at the Cleveland Clinic, Ohio. He has interest...

View all Leading Experts in this Study Group

GLG NewsSM Analyses by this Study Group's Leading Experts (?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Synta Drug for Metastatic Melanoma Not Dead Yet (?)

November 3, 2009

Eric Whitman, MD, Medical Director, Office of Grants and Research, ATLANTIC HEALTH SYSTEM INC

Synta Pharmaceuticals Announces Updated Elesclomol SYMMETRYSM Data Presented at Melanoma XIII | www.businesswire.com

Updated data presented at an annual Melanoma conference suggests the drug Elesclomol may benefit a subset of patients treated on a Phase III trial. This Synta Pharmaceuticals-sponsored trial in metastatic melanoma patients was stopped for safety (survival) concerns in February 2009, but the updated...

Delcath Phase III trial for metastatic melanoma completes enrollment

November 3, 2009

Eric Whitman, MD, Medical Director, Office of Grants and Research, ATLANTIC HEALTH SYSTEM INC

Delcath Systems, Inc. Completes Phase III Study Enrollment | www.reuters.com

The Delcath Systems Percutaneous Hepatic Perfusion (PHP) trial to treat patients with metastatic melanoma has completed enrollment and now must track patients, record data, and analyze results.This trial was apparently enrolled on schedule and the company is targeting 2010 for FDA regulatory submis...

Plexxikon Drug for Melanoma Continues to Show Great Promise

October 14, 2009

Eric Whitman, MD, Medical Director, Office of Grants and Research, ATLANTIC HEALTH SYSTEM INC

Researchers herald 'breakthrough' skin cancer therapy | www.fiercebiotech.com

The new drug PLX-4032, being developed by Plexxikon and Roche, continues to show impressive short term results in melanoma patients with specific BRAF mutations, with a reported 70% tumor response rate.

Triple negative Breast Cancer Strategies

October 14, 2009

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com

Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as fornon...

Farletuzumab (F) helps the ovarian cancer patients that do well, do well?

September 25, 2009

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com

F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we...

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Academic Institution*

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Physician - Director
  • Director
  • Physician - Division Head
  • Owner

Related Study Groups

Study Group Name No. Members
Oncologists who Treat Hematologic Malignancies (US) 858
Hematologists (US) 998
Hematologists and Oncologists in Private Practice (US) 461
Oncologists in Private Practice in the U.S. 450
Oncologists Specializing in Hematologic Malignancies in the U.S. 424
Breast Oncologists (US) 314
Oncologists who Treat Leukemia (US) 202